1. Introduction {#sec0005}
===============

In pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) *PAX5* is one of the most frequent targets affected by genetic alterations including deletions, point mutations, and gene rearrangements [@bib0005]. *PAX5* deletions and *PAX5* mutations are found in about 30% and 5--7% of the cases, respectively, and *PAX5* rearrangements in 2--3% [@bib0005; @bib0010; @bib0015; @bib0020]. *PAX5* rearrangements either result in *bona fide* in-frame fusions and the expression of chimeric transcripts [@bib0005; @bib0015; @bib0020] or in *PAX5* fusions to genes in opposite orientation, out-of-frame fusions or the expression of truncated isoforms [@bib0020].

To date, 16 different in-frame PAX5 fusion partners comprising a heterogeneous group of genes that encode transcription factors, structural proteins, the non-receptor tyrosine kinase JAK2, and several with so far unknown functions have been reported [@bib0005; @bib0015; @bib0020]. A unifying feature of all PAX5 fusion proteins is the retention of the PAX5 paired DNA-binding domain (PD), which is fused to either the entire fusion partner protein or its C-terminal portion [@bib0005; @bib0015; @bib0020].

While many of the *PAX5* fusions have so far only been observed in a couple of, or only single, cases, a number of them are more commonly found. The most frequently observed rearrangements are *PAX5-ETV6* and *PAX5-C20orf112* followed by *PAX5-ELN*, *PAX5-FOXP1*, and *PAX5-JAK2* each of which has been detected in at least three cases [@bib0005; @bib0015; @bib0020; @bib0025].

We here report the third case with a *PAX5-AUTS2* fusion resulting from unbalanced t(7;9)(q11.2;p13.2) rearrangements and summarize the clinical and laboratory characteristics of these patients.

2. Patient and methods {#sec0010}
======================

2.1. Case report {#sec0015}
----------------

A 7-month-old boy presented with 158 × 10^9^/L leucocytes in the peripheral blood (PB) and 91% and 89% blast cell infiltration in the PB and bone marrow (BM), respectively ([Table 1](#tbl0005){ref-type="table"}). The blast cells showed an L1 morphology and immunophenotyping established the diagnosis of a CD10^+^ BCP-ALL. Ninety percent of the blast cells were CD19 and CD10 positive and ∼10% weakly positive for cytoplasmic IgM; and they were negative for the myeloid markers CD13, CD15, CD33, and MPO and the T-cell markers cytoplasmic CD3 and surface CD7.

Because of a poor prednisone response at day 8 the patient was treated, with informed consent, in the high risk group (HRG) of the ALL-BFM 90 clinical trial. A complete morphologic remission (CR) was achieved after completion of induction therapy; however, 2.1 years after initial diagnosis the patient had a central nervous system (CNS) relapse. The patient achieved a second CR but died of an infectious complication 3.4 years after initial diagnosis. Cytogenetics of the PB showed a 46,XY,t(7;9)(q11;p13) karyotype, and fluorescence in situ hybridization (FISH) indicated a *PAX5* rearrangement. The patient\'s laboratory and clinical parameters are summarized in [Tables 1 and 2](#tbl0005 tbl0010){ref-type="table"}.

2.2. FISH and Reverse Transcription-Polymerase Chain Reaction {#sec0020}
-------------------------------------------------------------

FISH using *PAX5*-specific cosmid probes was conducted as described [@bib0015]. RT-PCR for the detection of *PAX5*-*AUTS2* transcripts was performed using primers PAX5ex5-F1 (5′-TACTCCATCAGCGGCATCC-3′) and AUTS2ex8-R1 (5′-TATTGGCTGTGCGACCTGAG-3′) located in exons 5 and 8 of *PAX5* and *AUTS2*, respectively; the amplification product was directly sequenced (Eurofins, MWG, Operon, Germany). The exon nomenclature used corresponds to that of the NCBI reference sequences *PAX5* NM_016734.1 and *AUTS2* NM_015570.2 (accessed March 2012).

2.3. *In silico* protein analysis {#sec0025}
---------------------------------

Protein analysis was performed using BLASTP and COBALT ([http://www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov/)), PSORTII ([http://psort.hgc.jp](http://psort.hgc.jp/)) and CAST (<http://athina.biol.uoa.gr/CAST/>). Further information regarding the AUTS2 protein family and posttranslational modifications were obtained from PRINTS (<http://www.bioinf.man.ac.uk/>) and the PhosphoSitePlus^®^ database ([http://www.phosphosite.org](http://www.phosphosite.org/)).

3. Results and discussion {#sec0030}
=========================

Interphase FISH of a pediatric BCP-ALL with a t(7;9)(q11;p13) using *PAX5*-specific probes detected a 3′-end deletion of the gene ([Fig. 1](#fig0005){ref-type="fig"}A) suggesting the presence of a *PAX5* fusion with a partner gene located at 7q11. Subsequent RT-PCR revealed the expression of *PAX5-AUTS2* transcripts, in which exon 6 of *PAX5* was fused to exon 6 of *AUTS2* ([Fig. 1](#fig0005){ref-type="fig"}B and C). Similar in-frame fusions of *PAX5* exon 6 to *AUTS2* exons 4 or 7 have been previously described [@bib0030; @bib0035]. Therefore, the breakpoints within *AUTS2* appear to be variable but that within *PAX5* consistently occurs in intron 6.

Since *PAX5* and *AUTS2* are transcribed in the same -- centromere to telomere -- orientation, a reciprocal translocation may generate the fusion gene. However, in two cases due to loss of the der(7) chromosome the translocation was unbalanced ([Table 1](#tbl0005){ref-type="table"}). This is also reflected by the detection of one of the cases by SNP arrays (No. 1; [Table 1](#tbl0005){ref-type="table"}), which can only indicate fusion genes in case of unbalanced rearrangements [@bib0030]. Karyotyping of this previously published case now confirmed loss of the der(7). The cytogenetically unbalanced translocations in two of the *PAX5-AUTS2* cases and loss of the *PAX5* 3′-end in the third one underline the observation that in the majority of *PAX5*-rearranged cases the reciprocal fusion transcripts are not expressed [@bib0015; @bib0020] and that, thus, the *PAX5*-partner fusions drive leukemogenesis [@bib0005].

The putative consensus chimeric protein deduced from the fusion transcripts not only contains the PAX5 PD, which is typically retained in all PAX5 fusion proteins [@bib0005; @bib0015; @bib0020], but also the octapeptide motif, the nuclear localization signal (NLS), and the homeodomain, which are fused to the C-terminal regions of AUTS2 ([Fig. 1](#fig0005){ref-type="fig"}D). With the exception of PAX5-ETV6, in which only the PAX5 PD is maintained, in several PAX5 fusions the breakpoint occurs in intron 5, therefore, also the NLS is present [@bib0005; @bib0020]. In the remaining PAX5 fusions the breakpoints are located within further downstream introns resulting in the retention of additional conserved protein domains [@bib0005; @bib0020]. Thus, PAX5-AUTS2 may belong to a subtype of PAX5 fusion proteins whose function might be distinct from those that retain only the PD.

*AUTS2*, which is expressed in the developing brain, has been described as autism susceptibility candidate gene 2 and its mutation has also been linked to autosomal dominant mental retardation [@bib0040]. The nuclear protein AUTS2 belongs to the fibrosin-1-like protein family, which consists of AUTS2, FBRS (fibrosin), and FBRSL1 (fibrosin-like 1), which share a so-called FIBROSIN1LPF 5-element fingerprint signature. Moreover, AUTS2 is highly conserved among species and harbors several putative NLSs, two proline- alternating with two histidine-rich regions, and two potential serine phosphorylation sites ([Fig. 1](#fig0005){ref-type="fig"}D); the function of the latter sites has, however, not been analyzed in detail yet. In the putative PAX5-AUTS2 chimeric protein almost the entire AUTS2 protein, except for the region containing the NLSs, is fused to PAX5 which retains its NLS ([Fig. 1](#fig0005){ref-type="fig"}D).

Regarding the clinical course, all three *PAX5-AUTS2* positive patients were assigned to different risk arms of the respective clinical trials. They all achieved a CR after completion of induction therapy; however, two of the patients experienced an early relapse and both patients died, one from an infectious complication in second CR and one from progressive leukemia after a further relapse. The third patient remains in first CR for more than two years after diagnosis ([Table 2](#tbl0010){ref-type="table"}).

The general rarity of recurrent *PAX5* fusion gene positive BCP-ALL precludes any conclusions regarding their prognostic value. Yet, although the number of patients is very small, it is interesting to note that two of the three *PAX5-AUTS2* patients had a CNS involvement either at the time of diagnosis or relapse and two patients experienced early relapses tentatively indicating that *PAX5-AUTS2* positive cases may have a rather poor outcome.

In summary, the description of now three cases with a *PAX5-AUTS2* fusion confirms its recurrence in pediatric BCP-ALL and emphasizes the importance of functional studies of *PAX5* fusion genes to understand the pathogenesis of this rare disease.
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![Molecular genetic analysis of *PAX5-AUTS2* positive case. (A) FISH using *PAX5*-specific cosmids showing a 3′-end deletion: 5′-end-specific clone (green signals); 3′-end-specific clone (red signals). (B) RT-PCR using primers located in *PAX5* exon 5 and *AUTS2* exon 8 resulting in amplification of *PAX5-AUTS2* fusion transcripts. M, molecular weight marker 100 bp ladder (Promega); lane 1, patient No. 3; lane 2, normal control; lane 3, no template control. (C) Sequence chromatogram of the *PAX5*-*AUTS2* fusion junction showing fusion between exon 6 of *PAX5* and exon 6 of *AUTS2*. (D) Schematic representation of the structure of PAX5 (top) and AUTS2 (bottom) wild-type proteins as well as the putative consensus chimeric protein (middle). PD, paired domain; OP, octapeptide; HD, homeodomain; TA, transactivation domain; I, inhibitory domain; H, histidine-rich regions; P, proline-rich region; arrows indicate nuclear localization signal (NLS); filled lollipops represent serine phosphorylation sites.](gr1){#fig0005}

###### 

Patient and laboratory data of *PAX5-AUTS2* positive cases.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Age (yrs)   Sex   WBC (×10^9^/L)   Blasts BM   Morphology/phenotype   Karyotype                                                Reference
  ----- ----------- ----- ---------------- ----------- ---------------------- -------------------------------------------------------- ---------------------------------------------------------------
  1     3.1         M     171.5            93%         L1/B-III               45,XY,-7,der(9)t(7;9)(q11;p13)\[15\]/46,XY\[1\]          Kawamata et al.[a](#tblfn0005){ref-type="table-fn"}[@bib0030]

  2     2.8         F     5.6              80%         L1/B-III               45,XX,-7,der(9)t(7;9)(q11;p13),dup(16)(p11p13)\[14\]/\   Coyaud et al. [@bib0035]
                                                                              46,XX\[2\]                                               

  3     0.6         M     158.0            89%         L1/B-II/III            46,XY,t(7;9)(q11;p13)\[8\]                               This work
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BM, bone marrow; WBC, white blood cell count; yrs, years.

Initially in this case no cytogenetic analysis was performed.

###### 

Clinical characteristics and outcome of *PAX5-AUTS2* positive cases.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Clinical trial                                   CNS disease   MRD day 33   MRD day 78   MRD risk   Prednisone response   CR day 33   Risk group   Relapse   Time to relapse (yrs)[a](#tblfn0010){ref-type="table-fn"}   Outcome   Follow-up (yrs)[b](#tblfn0015){ref-type="table-fn"}
  ----- ------------------------------------------------ ------------- ------------ ------------ ---------- --------------------- ----------- ------------ --------- ----------------------------------------------------------- --------- -----------------------------------------------------
  1     ALL-BFM 2000                                     Yes           10^−4^       Neg          IR         Good                  Yes         MRG          1st BM\   1.4\                                                        Dead      1.7
                                                                                                                                                           2nd BM    1.6                                                                   

  2     ALL-BFM 2000                                     No            Neg          Neg          LR         Good                  Yes         SRG          /         /                                                           1st CR    2.2+

  3     ALL-BFM 90[c](#tblfn0020){ref-type="table-fn"}   No            ND           ND           ND         Poor                  Yes         HRG          CNS       2.1                                                         Dead      3.4
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BM, bone marrow; CNS, central nervous system; CR, complete morphologic remission; MRD, minimal residual disease; ND, not determined; IR, intermediate risk; LR, low risk; MRG, medium risk group; SRG, standard risk group; HRG, high risk group; yrs, years.

From initial diagnosis.

Follow-up from initial diagnosis to date of death or last follow-up date.

In the ALL-BFM 90 trial MRD was not used as parameter for risk stratification.
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